HIGHLIGHTS
- who: Juan C. Almagro and collaborators from the Inc, Concord Ave, Cambridge, MA, USA have published the Article: Evolution of Anti-SARS-CoV-2 Therapeutic Antibodies, in the Journal: (JOURNAL) of 11/03/2020
- how: The lead molecules COV2-2130 and COV2-2196 precursors of Cilgavimab and Tixagevimab respectively were tested for their ability to block binding of the RBD to hACE-2 .
- future: And Future Directions Nine therapeutic antibodies have received EUA by the FDA and/or EMA to prevent and/or cure COVID-19.
SUMMARY
In parallel . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.